Sepracor, Inc.

Selecta Biosciences, Inc.

Janus Biotherapeutics, Inc.

Spectra Systems Corporation

Hemasure, Inc.

Steadfast Corporation

Flexplay Technologies, Inc.

Spectradisc Corporation

Seprachem, Inc.

Creative Biomolecules, Inc.

Coley Pharmaceutical Group, Inc.

Coley Pharmaceutical Gmbh

Spectra Science Corporation

Versicor, Inc.

Lipford, Grayson, B.

Charles M Zepp

Yun Gao

Grayson B Lipford

Nabil M Lawandy

David R Dodds

Donald L Heefner

Yaping Hong

Eric K Lee

Richard F Rossi

Kenneth S Norland

Stephen Alan Wald

Franco Castino

Andrei Smuk

Yves Fouron

Roger P Bakale

Lloyd Johnston

Sam Baldwin

Xiaoyi Nie

Mark J Keegan

Richard R Feinberg

Fen-ni Fu

Stephen L Matson

F Donald Roberts

Marianne Krieg-Kowald

Louis Locatell

Petr Ilyinskii

Timothy J Driscoll

Mark G Currie

Charles M Cohen

James S Huston

Jeffrey L Conroy

Robert L Bratzler

Robert S Afzal

Steven Brandt

William Goltsos

Steven W Jones

Alexandra Forsbach

Leif Olson

Abdul R Azad

Allison Berube

Jorge Luis Lopez

Robert A Dishman

Tim Driscoll

Jeff Conroy

Andrei Y Smuk

Alison Berube

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.

Immune system modulators

Provided herein are compounds and related composition and methods that may be used to raise an antibody response to nicotinic compounds, in some embodiments.

Modified nicotinic compounds and related methods

This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.

Immunomodulatory agent-polymeric compounds

The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. 

Imidazole quinoline-based immune system modulators

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

Dose selection of adjuvanted synthetic nanocarriers

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. 

A system and method for authentication of secure products is disclosed. The security feature contains a first component in the form of an emitter capable of emitting light in response to external pump light. The security feature also contains a second component in the form of a taggant that absorbs light in a spectrally narrow range compared to the broader excitation spectrum of the first material. In this manner the emitter and taggant work in combination with one another to create an emission response significantly dependent on the illumination wavelengths and unique to the specific combination of the components. The emitter and taggant can be in the form of a mixture. Further the emitter and taggant may be applied in close proximity to one another, such as within two separate coating layers on a suitable substrate.

Multi wavelength excitation/emission authentication and detection scheme

Systems and methods of providing a covert security marking for items such as documents, packaging, credit cards, and other valuable goods to combat the steady increase in forgery, counterfeiting, and other fraudulent activities is presented. A spectrally narrow, near infrared ink system serves as the basis of a covert security feature for items of value. Alternatively, or in combination, metal oxides having a substantially narrow absorption band and a maximum absorption wavelength of electromagnetic radiation in the near infrared range are also utilized.

Near infrared ink security feature

The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

Small molecule toll-like receptor (TLR) antagonists

Growing community of inventors

Hardwick, MA, United States of America

Charles M Zepp